Biotechnological drugs are a wide group of therapeutic agents obtained by means of genetic engineering methodologies. They act through the inhibition of specific cytokines/cells involved in the cascade of different pathological processes, leading to the modification of host immune response.

The main targets of these drugs are TNF-α, IL-6, IL-1, and B and T cells. In the latest years, according to the improved knowledge in the pathogenesis of several diseases, the use of these drugs is steadily increasing, and new agents have been marketed or are under development.

Autoimmune rheumatic diseases are the prototypical example of pathological conditions that may benefit from these therapies. Biotechnological drugs deeply improved patients’ prognosis and quality of life in several rheumatic conditions, as, for example, rheumatoid arthritis (RA). Despite the large number of papers published and the large clinical experience obtained for some of these drugs, there are still many questions that should be clarified. This special issue is addressed to the analysis of some peculiar aspects of these drugs, in both clinic and research context.

This forum is one of the top-ranked meetings in the field of biotechnological drugs in China. Through participating in it, you can learn more about the processing of technologies, the whole industry and the market of novel antibodies, antibody drugs, new vaccine development, new vaccine industry, protein modification in China. Welcome to this academic banquet! Bioon will try our best to provide an excellent platform for you to communicate with China's first-class experts and senior managers, as well as to expand your business in China!